News

Nativis Research Partner to Present at COGNO Conference in Australia

Nativis to Present at the Ladenburg Thalmann 2017 Healthcare Conference

Updates to include partnerships, clinical program progress and plans for 2018

SEATTLE September 20 – Nativis, Inc., a clinical stage life science bio-electronics company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, today announced that Chris E. Rivera, Nativis Chief Executive Officer, is scheduled to present at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017, at 1:30 p.m. ET. The conference will be held at the Sofitel New York Hotel.

Mr. Rivera will provide an overview and update of the Company’s progress during the first 3 quarters of 2017 and other activities at a live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Earlier this month, Nativis announced that based on encouraging safety and survival data, the current feasibility study in recurrent GBM, NAT-101, will be expanded to enroll up to 32 more patients affected by first or second recurrence in the combination therapy arm – i.e., Nativis Voyager® plus a standard chemotherapy drug.  This study will be conducted at 10 or more clinical sites in the US. In addition, a feasibility study in up to 11 patients newly diagnosed with GBM, NAT-109, will begin enrolling patients at multiple sites in the US.  In this new feasibility study, patients will be treated with Nativis Voyager® and standard of care – i.e., temozolomide and radiotherapy – following surgical resection.  The primary endpoint in both studies is safety, and secondary endpoints include assessment of overall survival and progression-free survival.

In April of this year, Nativis announced it had entered into an exclusive licensing agreement for the development and commercialization of Nativis’ proprietary ultra-low radio frequency energy (ulRFE®) technology for the potential treatment of Glioblastoma Multiforme (GBM) in the Japanese market, with Teijin Limited, a comprehensive Japanese company expanding businesses in high-performance materials, pharmaceuticals, home healthcare, product converting and information technology.

Institutional investors who would like to attend the Company’s presentation, please click on the link to the Ladenburg Thalmann 2017 Healthcare Conference for registration information.  Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

About Nativis, Inc.

Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use, non-invasive device called Nativis Voyager®. The Company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, glioblastoma), who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain.

Investor Relations Contact:
Lee Roth / Tram Bui
lroth@theruthgroup.com / tbui@theruthgroup.com
646-536-7012 / 7035

Media Relations Contact:
Aaron Blank / Amber Benson
ablank@feareygroup.com / abenson@feareygroup.com
206-343-1543

Back to News